Skip to main content
Clinical Trials/NCT02048930
NCT02048930
Completed
Not Applicable

Effectiveness and Cost-effectiveness Evaluation of Easyhaler Versus Other Devices in a Real World Primary Care Population

Research in Real-Life Ltd0 sites24,003 target enrollmentSeptember 2012
ConditionsAsthma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Asthma
Sponsor
Research in Real-Life Ltd
Enrollment
24003
Primary Endpoint
asthma control (excluding SABA usage)
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The aim of this study is to compare the clinical effectiveness and cost-effectiveness of the Easyhaler® (EH) device and other DPI devices commonly used in the UK in a UK primary care asthma population of patients aged 6 to 80 years.

Detailed Description

A recent observational study by Price et al carried out using the UK's General Practice Research Database (CPRD) to compare asthma-related outcomes for different inhaled corticosteroid (ICS) inhaler devices, using Easyhaler and dry powder inhalers (DPIs).

Registry
clinicaltrials.gov
Start Date
September 2012
End Date
March 2013
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Research in Real-Life Ltd
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients must also meet the following inclusion criteria:
  • (1) Aged: 6-80 years - stratified 6-11 years; 12-60 years; ≥61 years to allow paediatrics and adolescent / adult sub analyses; and to allow for the exclusion of elderly (aged 61+) smokers and ex-smokers if required.
  • (2) On-going asthma therapy: ≥2 prescriptions for asthma during the outcome period (i.e. ≥1 prescription (for any asthma therapy) in addition to the prescription for ICS at IPD (initiation / step-up/ switch).
  • (3) Evidence of active asthma:
  • Initiation - a diagnostic code for asthma
  • Step-up / Switch - ≥2 prescriptions for asthma (at least one of which is for ICS) at different points in time during the baseline year PLUS a diagnostic code for asthma.
  • (4) Have at least one year of up-to-standard (UTS) baseline data and at least one year of UTS outcome data (following the IPD).

Exclusion Criteria

  • Patients will be excluded from the analysis if they have:
  • (1) Had a COPD read code at any time; and/or
  • (2) Had any chronic respiratory disease, except asthma, at any time; and/or
  • (3) Patients on maintenance oral steroids during baseline year; and/or
  • (4) Multiple ICS prescriptions at IPD.

Outcomes

Primary Outcomes

asthma control (excluding SABA usage)

Time Frame: 1 year

The Composite proxy for asthma control (excluding SABA usage) during the one-year outcome period, which is defined as: Controlled: the absence of the following during the one-year outcome period: (i) Asthma-related : 1. Hospital attendance or admission 2. A\&E attendance, OR 3. Out of hours attendance, OR 4. Out-patient department attendance (ii) GP consultations for lower respiratory tract infection (iii) Prescriptions for acute courses of oral steroids ; Uncontrolled: all others.

exacerbations (ATS definition)

Time Frame: 1 year

Total number of asthma exacerbations (ATS Definition) defined as an occurrence of: (i) Asthma-related: 1. Hospital attendance / admissions OR 2. A\&E attendance (ii) Use of acute oral steroids.

exacerbations (Clinical definition)

Time Frame: 1 year

Total number of asthma exacerbations (Clinical Definition) defined as an occurrence of: (i) Asthma-related: 1. Hospital attendance / admissions, OR 2. A\&E attendance, OR (ii) GP consultations for lower respiratory related tract infections (iii) Use of acute oral steroids.

asthma control (including SABA usage)

Time Frame: 1 year

The Composite proxy for asthma control (including SABA usage) during the one-year outcome period, which is defined as: Controlled: the absence of the following during the one-year outcome period: (iv) Asthma-related : 1. Hospital attendance or admission 2. A\&E attendance, OR 3. Out of hours attendance, OR 4. Out-patient department attendance (v) GP consultations for lower respiratory tract infection (vi) Prescriptions for acute courses of oral steroids ; Plus: (vii) Average prescribed daily dose ≤200mg of Salbutamol / ≤500mg of terbutaline. Uncontrolled: all others.

Secondary Outcomes

  • treatment success definition 1(1 year)
  • SABA dosages(1 year)
  • adherence to ICS therapy(1 year)
  • Medication Possession Ratio (MPR)(1 year)
  • Treatment success (definition 2)(1 year)

Similar Trials